ArticleThe ocular surface2018
The immunoregulatory role of corneal epithelium-derived thrombospondin-1 in dry eye disease.
Article in The ocular surface, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Corneal lymphangiogenesis as a potential target in dry eye disease - a systematic review.Survey of ophthalmologyPooled it
- Immunomodulatory role and therapeutic potential of thrombospondin-1 during infectious diseases and autoimmunity.BMC biology · 2026Review
- THBS1 inhibition alleviates inflammatory response by inhibiting TGF-β and NLRP3 inflammasome in experimental murine dry eye.Medical molecular morphology · 2026Article
- Oral microbiota-responsive ZIF nanoplatform via double-layer glycans modified combined with PD-1 inhibitor for treatment of microsatellite-stable colorectal cancer.Materials today. Bio · 2025Article
- Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- MSC-encapsulated porous microparticle eye drops for autoimmune dry eye disease treatment in NOD mice.Science advances · 2025Article
- Topical delivery of a human single-domain antibody targeting IL-33 to inhibit mucosal inflammation.Cellular & molecular immunology · 2025Article
- The Various Roles of PEDF in Cancer.Cancers · 2024Review
- Transmembrane Protein CMTM6 Alleviates Ocular Inflammatory Response and Improves Corneal Epithelial Barrier Function in Experimental Dry Eye.Investigative ophthalmology & visual science · 2024Article
- Extending the use of biologics to mucous membranes by attachment of a binding domain.Communications biology · 2023Article
- Article
- An Overview of the Dry Eye Disease in Sjögren's Syndrome Using Our Current Molecular Understanding.International journal of molecular sciences · 2023Review
- Corneal Epithelium-Derived Netrin-1 Alleviates Dry Eye Disease via Regulating Dendritic Cell Activation.Investigative ophthalmology & visual science · 2022Article
- Immune regulation of the ocular surface.Experimental eye research · 2022Review
- Osteopontin contributes to virus resistance associated with type I IFN expression, activation of downstream ifn-inducible effector genes, and CCR2Frontiers in immunology · 2022Article
- Autoimmunity in dry eye disease - An updated review of evidence on effector and memory Th17 cells in disease pathogenicity.Autoimmunity reviews · 2021Review
- Fabrication, Rheological, and Compositional Characterization of Thermoresponsive Hydrogel from Cornea.Tissue engineering. Part C, Methods · 2021Article
- Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation.Scientific reports · 2021Article
- Experimental Pharmacotherapy for Dry Eye Disease: A Review.Journal of experimental pharmacology · 2021Review
- Recent Developments About the Pathogenesis of Dry Eye Disease: Based on Immune Inflammatory Mechanisms.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeIn this study, we examine the expression of corneal epithelium-derived thrombospondin-1 (TSP-1) and its immunomodulatory functions in a validated murine model of dry eye disease (DED).
methodsDED was induced in female C57BL/6 using a controlled environment chamber (CEC) for 14 days. mRNA and protein expression of TSP-1 by corneal epithelial cells was quantified using real-time PCR and flow cytometry. Corneal epithelial cells from either naïve or DED mice were cultured with bone marrow derived dendritic cells (BMDCs) in the presence of IFNγ for 48 h, and BMDC expression of MHC-II and CD86 was determined using flow cytometry. Next, either recombinant TSP-1 or anti-TSP-1 antibody was added to the co-culture, and BMDC expression of above activation markers was evaluated. Finally, either DED mice were topically treated with either recombinant TSP-1 or human serum albumin (HSA), and maturation of corneal DCs, expression of inflammatory cytokines, and DED severity were investigated.
resultsmRNA expression of TSP-1 by the corneal epithelium was upregulated in DED. Corneal epithelial cells derived from mice with DED demonstrated an enhanced capacity in suppressing BMDC expression of MHC-II and CD86 relative to wild type mice, and this effect was abrogated by TSP-1 blockade and potentiated by recombinant TSP-1. Finally, topical application of recombinant TSP-1 significantly suppressed corneal DC maturation and mRNA expression of pro-inflammatory cytokines, and ameliorated disease severity in mice with DED.
conclusionsOur study elucidates the function of epithelium-derived TSP-1 in inhibiting DC maturation and shows its translational potential to limit corneal epitheliopathy in DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.